Research programme: HDL-related therapeutics - Esperion/Cleveland Clinic

Drug Profile

Research programme: HDL-related therapeutics - Esperion/Cleveland Clinic

Alternative Names: 4 WF; Apolipoprotein A1-4 WF

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Esperion Therapeutics; The Cleveland Clinic Foundation
  • Developer Cleveland Clinic; Esperion Therapeutics
  • Class Peptides; Small molecules
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute coronary syndromes
  • No development reported Dyslipidaemias

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Dyslipidaemias in USA (PO)
  • 13 Mar 2014 Preclinical trials in Acute coronary syndromes in USA (Parenteral)
  • 01 Jul 2011 Early research in Acute coronary syndromes in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top